Home Latest Articles
Latest Articles
  • Chuan BA, Tuluhongjiang WUSUER, Xiaolei YANG, Bo SONG
    World Clinical Drug. 2022, 43(8): 1058-1062.
    Objective

    Cerebral vasospasm is a common postoperative complication in patients with cerebral aneurysms treated by endovascular embolization. This paper analyzes the clinical effect of fasudil combined with nimodipine in the prevention of this complication.

    Methods

    Total 80 patients with cerebral aneurysms who received endovascular embolization in Dushanzi People's hospital from January 1, 2019 to December 31, 2020 were randomly divided into control group and observation group, with 40 patients in each group. All patients were treated with nimodipine, and the observation group was treated with fasudil combined with nimodipine. The treatment effects of the two groups were compared.

    Results

    The total effective rates of the observation group were higher than that of control group (97.50% vs 80.00%, P<0.05). The modified Rankin scale (mRS) of observation group was significantly lower than that of control group [(0.90±0.15) vs (2.80±0.28), P<0.05]. The Glasgow Coma Scale (GCS) and Barthel score of observation group were significantly higher than those of control group [(14.49±0.80) vs (10.98±0.65), P<0.05], [(79.97±4.44) vs (55.82±3.35), P<0.05]. The mean blood flow of posterior cerebral artery (PCA) and middle cerebral artery (MCA) of observation group were significantly lower than those of control group [(38.41±1.76) vs (45.54±2.99) cm/s, P<0.05], [(81.44±2.24) vs (92.33±4.43)cm/s, P<0.05]. Matrix metalloprotein-9 (MMP-9) and nuclear factor kappa-B (NF-κB) of observation group were significantly lower than those of control group [(133.33±8.88) vs (165.44±10.55)nmol/L, P<0.05], [(0.12±0.01) vs (0.25±0.03)nmol/L, P<0.05]. There was no significant difference in the incidence of adverse reactions after treatment between the two groups P>0.05.

    Conclusion

    Fasudil combined with nimodipine in the treatment of cerebral aneurysms patients after intravascular interventional embolization can effectively reduce the risk of postoperative cerebral vasospasm, reduce arterial blood flow velocity and coma index, effectively improve neurological function, and control the level of serum inflammatory factors, with significant effect and high safety.

  • Lantuya WU, Lechaolu BAO
    World Clinical Drug. 2022, 43(8): 1063-1066.

    Acute pharyngitis is a common respiratory disease with multiple characteristics. Serious cases can cause systemic complications such as acute nephritis, rheumatic fever, sepsis, and even endanger life. Mongolian medicine have certain advantages in treating this disease. This article reviews the understanding and treatment principles of acute pharyngitis in Mongolian medicine, the commonly used prescriptions and typical good prescriptions of Qingyan Liuwei powder in Mongolian medicine, so as to provide reference for clinical application and development in the future.

  • Meiqi CHEN, Xiuhua CHEN, Juan WANG
    World Clinical Drug. 2022, 43(7): 815-819.

    Organoid is to cultivate tissue-derived adult stem cells into a self-organizing structures through three-dimensional (3D) culture technology, which are derived from pluripotent stem cells or progenitor cells of isolated organs. So far, many organoids have been successfully cultured from mouse and human stem cells. Under the 3D culture system, tumor organoids can be expanded, cryopreserved and genetically modified for a long time, and maintain genetic and phenotypic stability can be maintained in the process of expansion and cryopreservation, which has been widely used in the research of various tumors. This article reviews the development and research progress of tumor organoids.

  • Han LI, Yujing WANG, Meiqi CHEN, Xiuhua CHEN, Juan WANG
    World Clinical Drug. 2022, 43(7): 820-825.

    With the rapid development of immunology and immunotherapy, it is increasingly possible and important to understand the interaction and mechanism between immune cells and tumor cells in order to improve the clinical effect of immunotherapy and develop new treatment methods. Traditional two-dimensional cell culture has various limitations, and the new organoids summarize the complex environment of the original tissue, and are highly similar to the original tissue or organ in vivo in terms of genome and molecular markers. The co-culture system of organoids and immune cells creates an immune environment which mimics the tumor microenvironment in vivo and provides an ideal experimental platform for autoimmune diseases, tumor immune research and immunotherapy. This article reviewed the progress of the co-culture system of tumor organoids and immune cells and the mechanism of their interaction.

  • Yujing WANG, Han Li, Xiuhua CHEN, Juan WANG
    World Clinical Drug. 2022, 43(7): 826-830.

    As a new in vitro basic research model in recent years, organoids have complex structures and cell types similar to real organs, and can simulate the physiological function of primitive tissues or organs. As a special organ in human body, pancreas contains internal and external secretory glands. Although pancreatic ducts and islet like organs derived from adult tissues and pluripotent stem cells have been expanded in vitro for a long time, the development of pancreatic organoid technology still faces many challenges, and the establishment of complex pancreatic organoids closer to the real situation of human body is still a research difficulty that needs to be solved urgently. This paper reviewed the development of pancreas, the construction methods of existing pancreatic organoid models and their related applications.

  • Na NI, Yiyun YUAN, Qiurong CEN, Lizhu YI, Jiajun LI, Junlong WANG, Bing ZHOU
    World Clinical Drug. 2022, 43(7): 831-838.

    As one of the branches of genetics, epigenetics can affect the occurrence and progression of tumors through DNA methylation, chromatin remodeling, histone modification, non-coding RNA regulation, genomic imprinting, gene silencing, RNA editing and other mechanisms. The research and development of new drugs targeting epigenetics has become one of the hotspots of anti-cancer drugs. This article reviews the clinical research progress of epigenetic anti-cancer drugs in different therapeutic fields, combination therapy and researches in drug resistance, to provide an evidence for the follow-up research and clinical usage of these drugs.

  • Yan REN, Lu WANG, Ziwen DING, Junlong WANG, Jingyi FENG, Yunliang QIU, Na NI
    World Clinical Drug. 2022, 43(7): 839-843.

    Mesenchymal-epithelial transition factor (MET) is an important tumor driver gene in non-small cell lung cancer (NSCLC). In recent years, targeted therapy for MET signaling pathway has become a new target for lung cancer treatment. As the world's first oral, highly selective and potent MET inhibitor, tepotinib has been approved by Japan and the United States FDA for the treatment of advanced or recurrent NSCLC patients with unresectable and MET exon 14 skipping mutations. At the same time, it has shown good safety and efficacy in clinical studies. This article mainly reviewed the current clinical studies of tepotinib in NSCLC, liver cancer, NSCLC with brain metastasis and so on.

  • Tingting FU, Hong LUAN, Yanhong XU, Guijuan QIN, Bing LIU
    World Clinical Drug. 2022, 43(7): 844-850.
    Objective

    To investigate the effects of dihydromyricetin (DMY) on the proliferation, apoptosis of human lens epithelial cells SRA01/04 and its possible molecular mechanism.

    Methods

    SRA01/04 cells were divided into normal control (NC) group, DMY group, anti-miR-NC group, anti-miR-199b-5p group, miR-NC group, miR-199b-5p group, and DMY+miR-NC group and DMY+miR-199b-5p group. The expression level of miR-199b-5p was detected by quantitative reverse transcriptase-mediated polymerase chain reaction (qRT-PCR). Cell proliferation and apoptosis were detected by MTT assay and flow cytometry.

    Results

    DMY could inhibit the proliferation and induce apoptosis of SRA01/04 cells (P<0.05) and promote the expression of miR-199b-5p in SRA01/04 cells (P<0.05). Overexpressing miR-199b-5p could inhibit the proliferation and induce apoptosis of SRA01/04 cells (P<0.05). Inhibiting miR-199b-5p could promote the proliferation and inhibit apoptosis of SRA01/04 cells (P<0.05) and could reverse the proliferation inhibition and apoptosis promotion effects of DMY on SRA01/04 cells (P<0.05).

    Conclusions

    DMY can inhibit the proliferation and induce apoptosis of human lens epithelial cells SRA01/04, and the mechanism is related to the up-regulation of miR-199b-5p expression.

  • Xue LI, Zhijiao JIA, Hong JIANG
    World Clinical Drug. 2022, 43(7): 851-856.
    Objective

    To evaluate the therapeutic effect of batroxobin on rats with tinnitus and investigate its effect on neurotransmitters in inferior colliculus.

    Methods

    The tinnitus model was established by intraperitoneal injection of sodium salicylate combined with ''drinking water suppression''. The model rats were randomly divided into model group, positive control carbamazepine (5 mg/kg) and batroxobin (1 BU/kg) groups. Normal rats were arranged as the control group. After 15 days of intraperitoneal injection, the recovery time of drinking water suppression in each group was documented. The threshold value of auditory brainstem response (ABR) at different sound frequencies (4~28 kHz) in each rat was measured. The levels of γ-aminobutyric acid (GABA), 5-hydroxytrptamine (5-HT) and acetylcholine (ACh) in inferior colliculus in rats were detected by enzyme-linked immunosorbent assay (ELISA) and liquid chromatography/mass spectrometry (LC/MS), respectively.

    Results

    Compared with the model group, the recovery time of drinking water suppression in batroxobin group was significantly longer (P<0.01). Compared with the model group, the threshold value of ABR at different sound frequencies in batroxobin group were significantly reduced (P<0.05 or P<0.01). Compared with the model group, the GABA and ACh levels in inferior colliculus in batroxobin group were markedly increased (P<0.05 or P<0.01), while the 5-HT level was markedly decreased (P<0.01).

    Conclusion

    Batroxobin could relieve tinnitus symptoms induced by sodium salicylate in rats, which may be related to the regulation of central neural plasticity and recovery of the balance of excitatory/inhibitory neurotransmitters.

  • Chuan YUN, Dawei LI, Qianfei HAN, Han NA
    World Clinical Drug. 2022, 43(7): 857-862.
    Objective

    To investigate the effect of canagliflozin on connective tissue growth factor (CTGF) and monocyte chemotactic protein-1 (MCP-1) in diabetic nephropathy (DN) mice and its molecular mechanism.

    Methods

    Thirty C57BL/6 mice were randomly divided into normal control (NC, n=10) group and model group (n=20), streptozotocin (STZ) was used to construct DN model, after successful modeling, the mice were randomly divided into DN group and DN+canagliflozin (DN+C) group. The DN+C group was treated with canagliflozin by gavage, the DN and NC groups were given matching normal saline for 8 weeks. After 8 weeks, fasting blood glucose (FBG), 24 h urine protein (UP), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected, and the morphological changes of kidney tissue were observed. The mRNA and protein expressions of CTGF and MCP-1 were determined by quantitative reverse transcriptase-mediated polymerase chain reaction (qRT-PCR) and western blot, respectively.

    Results

    The levels of FBG, 24 h UP, BUN and Scr in model group were significantly increased (P<0.05). Compared with NC group, the levels of FBG, 24 h UP, BUN in DN+C group were significantly decreased (P<0.05). The glomerular and tubular basement membranes in DN group were thickened, and the extracellular matrix of the glomerulus was infiltrated by inflammatory cells. The pathological changes in DN+C group were less than those in DN group. Compared with NC group, the mRNA and protein expression of CTGF and MCP-1 in DN group were significantly increased (P<0.05); compared with DN group, the mRNA and protein expression of CTGF and MCP-1 in DN+C group were significantly decreased (P<0.05).

    Conclusion

    Canagliflozin can improve the high glucose state of DN mice, protect renal function, and delay the progression of DN. The mechanism may be related to the reduction of CTGF and MCP-1 expression.

News